ECUO PLWH, a regional network of communities living with HIV across 15 Eastern Europe and Central Asia countries, welcomes the extension of the MPP’s licence for bictegravir, tenofovir and other HIV medicines to include Ukraine and Belarus, countries that face numerous barriers to the access of inexpensive generic forms of HIV medicines. ECUO supports the strategy of the Medicines Patent Pool to scale up access to HIV, hepatitis C and tuberculosis medicines for our countries.
Vladimir Zhovtyak, President of ECUO PLWH (East Europe and Central Asia Union of People Living with HIV) 04 October 2017
The availability of generic atazanavir will bring more treatment options for PLHIV in Indonesia. Considering that atazanavir has lower pill counts and more favourable effects on lipid levels than existing protease inhibitors used in-country, its availability is beneficial.
Edo Agustian, National Coordinator, Indonesia Drug User Network 25 July 2017
This [expansion of the BMS atazanavir licence] is great news for Malaysia as it provides a very interesting option for affordable second-line treatment.
Edward Low, Director of the Positive Malaysian Treatment Access & Advocacy Group (MTAAG+) 25 July 2017
Since the first company (Gilead) joined in 2012, the MPP has been the central independent driver of access-oriented licensing in the pharma industry. Companies with the most pro-access criteria in their agreed licences have all negotiated agreements through the MPP (AbbVie, Bristol-Myers Squibb, Gilead, GSK and Merck & Co., Inc.).
Access to Medicine Index 01 November 2016
This is an important milestone in the treatment of hepatitis C and we congratulate BMS and the MPP on their agreement to bring essential medicines to low- and middle-income countries at affordable prices. Going forward we urge the MPP and other pharmaceutical companies to include more hepatitis C medicines in the patent pool in order to eliminate one of the world’s leading health concerns
Raquel Peck, CEO, World Hepatitis Alliance 01 November 2015
We are delighted that ViiV has reacted positively to our request and has included Ukraine into the MPP licence for paediatric abacavir, an important medicine for children living with HIV. Given the current situation in Ukraine, initiatives that result in access to lower priced ARVs are particularly important.
All Ukrainian Network of People Living with HIV/AIDS 01 November 2014
With only one in four children living with HIV currently getting treatment, we cannot continue to do business as usual” (…). “We congratulate MPP and Gilead on this expanded collaboration and their proactive efforts to support countries and populations hardest hit by HIV and AIDS. This is the kind of innovative action that we need now to protect the health of affected children and in order to achieve an AIDS-free generation.
Charles Lyons, President and CEO, Elizabeth Glaser Paediatric AIDS Foundation 01 July 2014
Members of the Interfaith Center on Corporate Social Responsibility (ICCR) and shareholders are applauding Roche on its recent agreement with the Medicines Patent Pool (MPP). (…) Shareholders consider the MPP to be an important program to help address the access to medicines issues thus facilitating efforts of pharmaceutical companies to meet their moral obligation to the health needs of the world’s most vulnerable.
Interfaith Center on Corporate Social Responsibility (ICCR) 01 August 2013
Chronic hepatitis C affects approximately 71 million people globally, with Egypt suffering from one of the highest burdens. Ravidasvir, in combination with other hepatitis C treatments, could support new national as well as global goals to eliminate the virus.
Dr. Sherine Helmy, CEO, Pharco Pharmaceuticals 21 April 2017
We are happy to work together with the MPP and Bristol-Myers Squibb (BMS) to improve health outcomes by providing access to new and affordable therapies to developing countries.
Pankaj R. Patel, Zydus Chairman and Managing Director 01 July 2016
Desano welcomes the opportunity of supporting increased volumes of this crucial treatment for people living with HIV/AIDS in Africa, and specifically for South Africa, which has the largest HIV treatment programme in the world
Tun Guo, Desano Director and Company Secretary 01 July 2016
ViiV Healthcare has worked with the Medicines Patent Pool for many years and we are pleased to continue our work with the organisation to further improve access to innovative medicines to address the burden of HIV. It is also a great testament to the success we have had working with the MPP that GSK is now looking at expanding this collaboration for access to medicines beyond HIV treatments.
Dominique Limet, CEO, ViiV Healthcare 01 April 2016
The MPP is an innovative mechanism for increasing access to both patented pipeline and existing medicines (…) Our three-year collaboration has been very successful thus far. Countries eligible for generic competition for TDF (tenofovir dixoproxil fumarate), for example, have increased dramatically to the ultimate benefit of many national treatment programmes in key resource-limited countries.
Gregg Alton, Executive Vice President, Corporate and Medical Affairs for Gilead Sciences 01 July 2014
We are excited about both the public health and business opportunities provided by the Patent Pool licences. Aurobindo looks forward to increasing its manufacture of HIV-related products, and expanding its work to cover promising new treatments, for the millions of people living with HIV across the globe.
P.V. Ramaprasad Reddy, Chairman, Aurobindo 01 October 2011
Successful cooperation of the Ministry of Health of Belarus with the Medicines Patent Pool is crucial in light of our current work to achieve the “90-90-90” goals and put an end to the epidemic in the country which is only possible when access to affordable and quality assured medicines is increased. Generic Bictegravir as well as other medicines for treating HIV, which Belarus will be able to procure due to the MPP’s agreement, are very much needed for the country.
Valery Malashko, Minister of Health of Belarus 04 October 2017
We are grateful for MPP efforts to ensure the availability and quality of guaranteed HIV treatment for Ukrainian patients and we hope to further expand access to innovative medicines for the treatment of HIV infections, viral hepatitis C and tuberculosis.
Dr. Ulana Suprun, Minister of Health, Ukraine 25 July 2017
The inclusion of Morocco in the MPP-ViiV licence on dolutegravir is great news for us.  Dolutegravir is a very interesting new treatment that could play an important role in the HIV response in our country.  Having access to the drug at affordable prices is key and we congratulate both parties for this important  agreement.
Houssaine Louardi, Minister of Health of the Kingdom of MOROCCO 01 April 2016
PEPFAR [the President’s Emergency Plan for AIDS Relie] applauds the new MSD licence as part of international efforts to greatly improve the lives of infants and children living with HIV/AIDS. Without antiretroviral treatment, 50 percent of infants living with HIV/AIDS will die by the age of two, and 80 percent by the age of five.
Ambassador Deborah L. Birx, M.D. United States Global AIDS Coordinator and United States Representative for Global Health Diplomacy 01 February 2015
On the occasion of World AIDS Day, France expresses its solidarity with the 35 million people living with HIV. It welcomes the signing – announced today – of a new agreement between the Medicines Patent Pool and the laboratory AbbVie. This will provide access, at an affordable price, to antiretroviral drugs for children (lopinavir/ritonavir).  
French Ministry of Foreign Affairs and International Development 01 December 2014
Of the 3.2 million children with HIV in the world, more than 90% live in sub-Saharan Africa with South Africa bearing a significantly high burden. (…) New adapted treatments of LPV/r and other medicines are urgently needed to end the HIV paediatric crisis. We are thus very pleased with the [MPP-AbbVie] agreement signed today.
South African Minister of Health, Aaron Mostoaledi 01 December 2014
Unitaid strongly supports the TB Alliance-Medicines Patent Pool collaboration to jump-start the clinical development of the new tuberculosis treatment sutezolid. This World Tuberculosis Day, we must re-double efforts to find better, faster-acting treatment solutions, especially for resistant forms of the disease.
Lelio Marmora, Executive Director, Unitaid 24 March 2017
After 5 years of operation of the MPP, millions of people have benefited and impressive financial savings have been achieved. The Commission concludes that there is great potential for expanding access to other new essential medicines through licensing of patents through patent pooling.
The Lancet Commissions on Essential Medicines for Universal Health Coverage 01 November 2016
To allow a competitive market, license agreements need to cover a broad territory, be non-exclusive, and include a number of generics-producing companies. They should be made public and ideally be negotiated through the Medicines Patent Pool to ensure transparency, and include pro-competitive, public health-friendly terms and conditions. View More
Global report on access to Hepatitis C Treatment 16 October 2016
The level of transparency in licensing agreements executed by the UNITAID-backed Medicines Patent Pool (MPP), in which all licences are publicly available, is laudable and rare. Voluntary licences can be an important enabler of treatment access. For example, in less than four years, licences negotiated through the MPP are estimated to have generated US$ 120 million in savings globally and supplied seven million patient-years of WHO-recommended ARV medicines.
United Nations High Level Panel on Access to Medicines 01 September 2016
The demand for affordable HIV treatment has resulted in comprehensive price reduction strategies for HIV medicines that may be applied to other medicines, diagnostics and health commodities. Strategies include fostering generic competition, including through, where appropriate, voluntary licences that include pro-access terms and conditions such as those negotiated by the Medicines Patent Pool. View More
WHO Global Health Sector Strategy on HIV, 2016–2021 01 June 2016
We, Heads of Government and representatives of States and Governments, welcome the broadening of the scope of work of the Medicines Patent Pool, hosted by UNITAID, to promote voluntary partnerships to address Hepatitis C and tuberculosis, reflecting the importance of integrating the AIDS response into the broader global health agenda. Vie More
United Nations General Assembly, Political Declaration on HIV/AIDS 01 June 2016
The Medicines Patent Pool was established following a recommendation of the WHO Global strategy and plan of action for public health, innovation and intellectual property. The Pool, which marks its fifth anniversary this year, has produced a remarkable track record in using license agreements to improve access to HIV treatments in middle-income as well as low-income countries. I welcome the intention of this Pool to extend its work to negotiate licensing agreements that expand access to tuberculosis and hepatitis C treatments. View More
Margaret Chan, WHO Director-General: Addressing Symposium on Intellectual Property and Trade 01 October 2015
Unitaid applauds today’s agreement by ViiV and the MPP to address the specific needs of children living with HIV. Incorporating palatable, child-friendly medicine options into paedriatic HIV programmes could significantly enhance and prolong children’s lives.
Philippe Douste Blazy, Chair, Unitaid 01 April 2014
The Joint United Nations Programme on HIV/AIDS (UNAIDS) welcomes the new collaboration between the Medicines Patent Pool and ViiV Healthcare to increase access to antiretroviral therapy for children. The new agreement is a significant step forwards in HIV treatment for children as very few antiretroviral drugs are formulated for paediatric use.
UNAIDS 01 February 2013
Voluntary use, where appropriate, of […] patent pools benefiting all developing countries, including through entities such as the Medicines Patent Pool, [is encouraged] to help reduce treatment costs and encourage development of new HIV treatment formulations, including HIV medicines and point-of-care diagnostics, in particular for children.
United Nations General Assembly Political Declaration on HIV/Aids 01 June 2011